Duyuru • Jun 11
ReproCELL Incorporated to Report Q1, 2027 Results on Aug 13, 2026 ReproCELL Incorporated announced that they will report Q1, 2027 results on Aug 13, 2026 Duyuru • May 29
ReproCELL Incorporated announced that it expects to receive ¥1.50505424 billion in funding from CVI Investments, Inc. Reprocell has announced to 11,728,000 shares at an issue price of ¥127 per share for gross proceeds of ¥1,489,456,000 and 29,320 17th series of stock acquisition rights at an issue price of ¥133 per unit, 29,320 18th series of stock acquisition rights at an issue price of ¥133 per unit, 29,320 19th series of stock acquisition rights at an issue price of ¥133 per unit and 29,320 20th series of stock acquisition rights at an issue price of ¥133 per unit for gross proceeds of ¥15,598,240 for total aggregates of ¥1,505,054,240 on May 27, 2026. The transaction includes new investor participation from CVI Investments. The exercise period starts from June 12 to June 11, 2030 with initial price of ¥170 per share. The transaction is expected to close on October 5, 2026. Reported Earnings • May 19
Full year 2026 earnings released: JP¥6.24 loss per share (vs JP¥1.11 profit in FY 2025) Full year 2026 results: JP¥6.24 loss per share (down from JP¥1.11 profit in FY 2025). Revenue: JP¥2.23b (down 25% from FY 2025). Net loss: JP¥591.0m (down JP¥694.0m from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Duyuru • May 14
ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026 ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026. New Risk • May 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.8b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (JP¥15.8b market cap, or US$99.9m). Duyuru • Mar 05
Reprocell Launches Gmp Master Cell Bank Manufacturing For Clinical Ipscs REPROCELL announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility, REPROCELL offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from StemRNA clinical seed iPSC manufacturing and StemEdit gene editing to GMP Master Cell Bank (MCB) production in compliance with FDA standards. By unifying these critical steps, REPROCELL enables cell therapy developers to accelerate IND submissions while reducing regulatory and manufacturing uncertainty. As part of this platform, the StemRNA Clinical iPSC Seed Clone – LLF-34-F3, derived from US sourced donor material, is supported by an active FDA Drug Master File (DMF). This clone has been expanded into a GMP MCB using FDA-compliant closed system processes. This off-the-shelf GMP iPSC MCB is available for commercial use, providing ready-to-use clinically validated starting material. For sponsors requiring European alignment, REPROCELL offers MCB/WCB manufacturing through its partner, Histocell. This service operates with a GMP certificate and authorization from the Spanish Agency for Medicines and Medical Devices (AEMPS) under European Medicines Agency (EMA) oversight. Donor sourcing and eligibility meet FDA, EMA, and PMDA requirements with full consent for therapeutic use. Footprint-free proprietary RNA reprogramming to generate StemRNA Clinical iPSC Seed Clones under FDA/EMA/PMDA requirements. US-generated StemRNA Clinical Seed Clones supported by an active FDA DMF. Genetic integrity and oncogenic risk assessment using whole-genome sequencing (WGS) for StemRNA Clinical Seed Clones. StemEdit clinical gene editing service, engineered for high on target efficiency with reduced off target activity and lower predicted immunogenicity. GMP MCB manufacturing in compliance with FDA or under EMA and PMDA authorization to manufacture. StemRNA Clinical iPSC Seed Clone – LLF-34-F3 is derived from a healthy O+ female US donor, fully consented for commercial and therapeutic use, and is homozygous at HLA-A and HLA-DPA1 loci enhancing its potential for allogeneic applications. The seed clone meets FDA, EMA and PMDA standards and is supported by a DMF while GMP MCB expansion uses FDA-compliant processes providing a traceable clinically ready starting material. REPROCELL also offers options of StemRNA Clinical iPSC Seed Clones from different donor profiles. This work was supported by a Commercialization Grant (no. 2024-MSCRFCO-6418) from the Maryland Stem Cell Research Fund (MSCRF). New Risk • Feb 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: JP¥0.30 (vs JP¥0.78 in 3Q 2025) Third quarter 2026 results: EPS: JP¥0.30 (down from JP¥0.78 in 3Q 2025). Revenue: JP¥635.0m (down 15% from 3Q 2025). Net income: JP¥28.0m (down 62% from 3Q 2025). Profit margin: 4.4% (down from 9.8% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Duyuru • Dec 09
ReproCELL Incorporated to Report Q3, 2026 Results on Feb 12, 2026 ReproCELL Incorporated announced that they will report Q3, 2026 results on Feb 12, 2026 Reported Earnings • Nov 17
Second quarter 2026 earnings released: JP¥1.92 loss per share (vs JP¥0.31 loss in 2Q 2025) Second quarter 2026 results: JP¥1.92 loss per share (further deteriorated from JP¥0.31 loss in 2Q 2025). Revenue: JP¥499.0m (down 29% from 2Q 2025). Net loss: JP¥182.0m (loss widened JP¥153.0m from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Nov 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.2b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (JP¥15.2b market cap, or US$98.6m). Duyuru • Sep 02
ReproCELL Incorporated to Report Q2, 2026 Results on Nov 13, 2025 ReproCELL Incorporated announced that they will report Q2, 2026 results on Nov 13, 2025 Reported Earnings • Aug 15
First quarter 2026 earnings released: JP¥3.21 loss per share (vs JP¥0.84 loss in 1Q 2025) First quarter 2026 results: JP¥3.21 loss per share (further deteriorated from JP¥0.84 loss in 1Q 2025). Revenue: JP¥475.0m (down 23% from 1Q 2025). Net loss: JP¥304.0m (loss widened 305% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Duyuru • Jun 27
ReproCELL Incorporated to Report Q1, 2026 Results on Aug 13, 2025 ReproCELL Incorporated announced that they will report Q1, 2026 results on Aug 13, 2025 Duyuru • May 14
ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025 ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025. New Risk • Mar 21
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥14.6b (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.6b market cap, or US$98.1m). Duyuru • Mar 05
ReproCELL Incorporated to Report Fiscal Year 2025 Results on May 14, 2025 ReproCELL Incorporated announced that they will report fiscal year 2025 results on May 14, 2025 Reported Earnings • Feb 15
Third quarter 2025 earnings released: EPS: JP¥0.78 (vs JP¥0.14 loss in 3Q 2024) Third quarter 2025 results: EPS: JP¥0.78 (up from JP¥0.14 loss in 3Q 2024). Revenue: JP¥748.0m (up 19% from 3Q 2024). Net income: JP¥73.0m (up JP¥85.0m from 3Q 2024). Profit margin: 9.8% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Duyuru • Dec 10
ReproCELL Incorporated to Report Q3, 2025 Results on Feb 13, 2025 ReproCELL Incorporated announced that they will report Q3, 2025 results on Feb 13, 2025 Reported Earnings • Nov 19
Second quarter 2025 earnings released: JP¥0.31 loss per share (vs JP¥0.14 loss in 2Q 2024) Second quarter 2025 results: JP¥0.31 loss per share (further deteriorated from JP¥0.14 loss in 2Q 2024). Revenue: JP¥701.0m (up 19% from 2Q 2024). Net loss: JP¥29.0m (loss widened 142% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (JP¥9.70b market cap, or US$63.6m). Duyuru • Aug 27
ReproCELL Incorporated to Report Q2, 2025 Results on Nov 13, 2024 ReproCELL Incorporated announced that they will report Q2, 2025 results on Nov 13, 2024 Reported Earnings • Aug 18
First quarter 2025 earnings released: JP¥0.84 loss per share (vs JP¥0.85 profit in 1Q 2024) First quarter 2025 results: JP¥0.84 loss per share (down from JP¥0.85 profit in 1Q 2024). Revenue: JP¥619.0m (up 11% from 1Q 2024). Net loss: JP¥75.0m (down 204% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. New Risk • Jul 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (JP¥12.4b market cap, or US$76.7m). Duyuru • Jun 06
ReproCELL Incorporated to Report Q1, 2025 Results on Aug 13, 2024 ReproCELL Incorporated announced that they will report Q1, 2025 results on Aug 13, 2024 Reported Earnings • May 16
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: JP¥0.36 loss per share (improved from JP¥3.62 loss in FY 2023). Revenue: JP¥2.43b (down 18% from FY 2023). Net loss: JP¥31.0m (loss narrowed 90% from FY 2023). Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) exceeded analyst estimates by 88%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Duyuru • May 15
ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024 ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024. New Risk • Mar 31
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (JP¥14.0b market cap, or US$92.6m). New Risk • Mar 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: JP¥218m Forecast net loss in 2 years: JP¥57m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (JP¥14.4b market cap, or US$97.8m). Duyuru • Mar 02
ReproCELL Incorporated to Report Fiscal Year 2024 Results on May 13, 2024 ReproCELL Incorporated announced that they will report fiscal year 2024 results on May 13, 2024 Reported Earnings • Feb 10
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: JP¥0.14 loss per share (improved from JP¥1.26 loss in 3Q 2023). Revenue: JP¥629.0m (down 2.8% from 3Q 2023). Net loss: JP¥12.0m (loss narrowed 89% from 3Q 2023). Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates by 85%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. New Risk • Dec 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥14.0b (US$96.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Market cap is less than US$100m (JP¥14.0b market cap, or US$96.7m). Duyuru • Dec 03
ReproCELL Incorporated to Report Q3, 2024 Results on Feb 09, 2024 ReproCELL Incorporated announced that they will report Q3, 2024 results on Feb 09, 2024 New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 11
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: JP¥0.14 loss per share (down from JP¥0.31 profit in 2Q 2023). Revenue: JP¥591.0m (down 35% from 2Q 2023). Net loss: JP¥12.0m (down 146% from profit in 2Q 2023). Revenue exceeded analyst estimates by 4.9%. Earnings per share (EPS) also surpassed analyst estimates by 93%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Major Estimate Revision • Sep 08
Consensus estimates of losses per share improve by 20% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥2.74b to JP¥2.77b. EPS estimate increased from -JP¥1.17 per share to -JP¥0.94 per share. Biotechs industry in Japan expected to see average net income growth of 33% next year. Consensus price target of JP¥270 unchanged from last update. Share price was steady at JP¥253 over the past week. Duyuru • Aug 25
ReproCELL Incorporated to Report Q2, 2024 Results on Nov 10, 2023 ReproCELL Incorporated announced that they will report Q2, 2024 results on Nov 10, 2023 Reported Earnings • Aug 12
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: EPS: JP¥0.85 (up from JP¥0.51 in 1Q 2023). Revenue: JP¥556.0m (down 17% from 1Q 2023). Net income: JP¥72.0m (up 71% from 1Q 2023). Profit margin: 13% (up from 6.3% in 1Q 2023). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Duyuru • May 28
ReproCELL Incorporated to Report Q1, 2024 Results on Aug 10, 2023 ReproCELL Incorporated announced that they will report Q1, 2024 results on Aug 10, 2023 Breakeven Date Change • May 23
Forecast to breakeven in 2025 The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 48% to 2024. The company is expected to make a profit of JP¥30.0m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule. Reported Earnings • May 16
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: JP¥3.62 loss per share (improved from JP¥7.57 loss in FY 2022). Revenue: JP¥2.95b (up 32% from FY 2022). Net loss: JP¥305.0m (loss narrowed 47% from FY 2022). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 2 years compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • May 14
ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023 ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023. Major Estimate Revision • Apr 13
Consensus estimates of losses per share improve by 56% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from JP¥2.65b to JP¥2.81b. EPS estimate increased from -JP¥1.88 per share to -JP¥0.82 per share. Biotechs industry in Japan expected to see average net income growth of 33% next year. Consensus price target of JP¥300 unchanged from last update. Share price rose 6.6% to JP¥242 over the past week. Reported Earnings • Feb 12
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: JP¥1.26 loss per share (improved from JP¥1.94 loss in 3Q 2022). Revenue: JP¥647.0m (up 30% from 3Q 2022). Net loss: JP¥107.0m (loss narrowed 29% from 3Q 2022). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 37%. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Duyuru • Dec 18
ReproCELL Incorporated to Report Q3, 2023 Results on Feb 10, 2023 ReproCELL Incorporated announced that they will report Q3, 2023 results on Feb 10, 2023 Price Target Changed • Nov 16
Price target decreased to JP¥300 Down from JP¥520, the current price target is provided by 1 analyst. New target price is 20% above last closing price of JP¥249. Stock is up 7.8% over the past year. The company is forecast to post a net loss per share of JP¥2.07 next year compared to a net loss per share of JP¥7.57 last year. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 11
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: EPS: JP¥0.31 (up from JP¥1.08 loss in 2Q 2022). Revenue: JP¥910.0m (up 50% from 2Q 2022). Net income: JP¥26.0m (up JP¥105.0m from 2Q 2022). Profit margin: 2.9% (up from net loss in 2Q 2022). Revenue exceeded analyst estimates by 48%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Aug 17
Consensus revenue estimates increase by 11% The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from JP¥2.38b to JP¥2.63b. Forecast losses expected to reduce from -JP¥3.04 to -JP¥2.07 per share. Biotechs industry in Japan expected to see average net income growth of 29% next year. Consensus price target of JP¥300 unchanged from last update. Share price rose 20% to JP¥244 over the past week. Reported Earnings • Aug 12
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: EPS: JP¥0.51 (up from JP¥1.70 loss in 1Q 2022). Revenue: JP¥666.0m (up 74% from 1Q 2022). Net income: JP¥42.0m (up JP¥164.0m from 1Q 2022). Profit margin: 6.3% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 80%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is expected to shrink by 4.4% compared to a 171% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jul 13
Consensus revenue estimates increase by 21% The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from JP¥1.97b to JP¥2.38b. Forecast losses expected to reduce from -JP¥3.27 to -JP¥3.04 per share. Biotechs industry in Japan expected to see average net income growth of 32% next year. Consensus price target of JP¥300 unchanged from last update. Share price was steady at JP¥213 over the past week. Reported Earnings • May 16
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: JP¥7.57 loss per share (up from JP¥11.37 loss in FY 2021). Revenue: JP¥2.23b (up 74% from FY 2021). Net loss: JP¥575.0m (loss narrowed 29% from FY 2021). Revenue exceeded analyst estimates by 8.4%. Earnings per share (EPS) missed analyst estimates by 67%. Over the next year, revenue is expected to shrink by 12% compared to a 212% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Breakeven Date Change • Apr 27
No longer forecast to breakeven The analyst covering ReproCELL no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of JP¥220.0m in 2024. New forecast suggests the company will make a loss of JP¥140.0m in 2024. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 12
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2022 results: JP¥1.94 loss per share (up from JP¥4.10 loss in 3Q 2021). Revenue: JP¥499.0m (up 49% from 3Q 2021). Net loss: JP¥150.0m (loss narrowed 49% from 3Q 2021). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 79%. Over the next year, revenue is forecast to grow 31%, compared to a 1,826% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Nov 15
Second quarter 2022 earnings released: JP¥1.08 loss per share (vs JP¥2.20 loss in 2Q 2021) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: JP¥607.0m (up 36% from 2Q 2021). Net loss: JP¥79.0m (loss narrowed 50% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jun 05
Consensus EPS estimates increase to -JP¥5.46 The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from JP¥1.87b to JP¥1.92b. EPS estimate increased from -JP¥11.46 to -JP¥5.46. Biotechs industry in Japan expected to see average net income growth of 29% next year. Consensus price target of JP¥520 unchanged from last update. Share price fell 17% to JP¥339 over the past week. Breakeven Date Change • Jun 04
Forecast to breakeven in 2024 The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of JP¥150.0m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule. Reported Earnings • May 14
Full year 2021 earnings released: JP¥11.37 loss per share (vs JP¥14.26 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.29b (up 7.3% from FY 2020). Net loss: JP¥812.0m (loss narrowed 20% from FY 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 26
New 90-day low: JP¥384 The company is down 2.0% from its price of JP¥391 on 27 November 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 3.0% over the same period. Reported Earnings • Feb 14
Third quarter 2021 earnings released: JP¥4.10 loss per share (vs JP¥3.18 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: JP¥335.0m (up 2.4% from 3Q 2020). Net loss: JP¥293.0m (loss widened 29% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Analyst Estimate Surprise Post Earnings • Feb 14
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Over the next year, revenue is forecast to grow 37%, compared to a 444% growth forecast for the Biotechs industry in Japan. Is New 90 Day High Low • Jan 25
New 90-day high: JP¥449 The company is up 17% from its price of JP¥384 on 27 October 2020. The Japanese market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. Reported Earnings • Nov 14
Second quarter 2021 earnings released: JP¥2.20 loss per share The company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: JP¥446.0m (up 45% from 2Q 2020). Net loss: JP¥157.0m (loss narrowed 24% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Oct 22
New 90-day low: JP¥373 The company is down 9.0% from its price of JP¥409 on 22 July 2020. The Japanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. Reported Earnings • Oct 01
First quarter earnings released Over the last 12 months the company has reported total losses of JP¥995.0m, with losses widening by 33% from the prior year. Total revenue was JP¥1.11b over the last 12 months, up 1.9% from the prior year.